medicines
-
18-Apr-2018 IP Watch
Dozens of NGOs oppose proposed EU watch list on IP rights
A wide-ranging list of international nongovernmental organisations issued a letter to European Trade Commissioner Cecilia Malmström opposing a proposal to establish a “watch list” of countries deemed failing to protect European intellectual property.
-
12-Apr-2018 The Guardian
Costly medicines and pus in milk: a Brexit trade deal that’ll make you sick
The US trade barriers list shows that Liam Fox could let more than just chlorinated chicken into the UK. The public deserve to know the details
-
11-Apr-2018 MSF Access Campaign
MSF statement on resumption of EU-India FTA negotiations
Officials from the European Union (EU) and India are expected to meet in Brussels on April 12th to resume technical talks on the long-stalled EU-India free trade agreement (FTA). A leaked draft of the agreement, which has been under discussion since 2007, contains proposals from the EU that push for intellectual property (IP) provisions in the FTA that could jeopardize access to affordable medicines.
-
29-Mar-2018 Public Citizen
Renegociación del TLCAN: Amenazas a medicinas asequibles
El TLCAN de 1993 fue el primer acuerdo “comercial” que incluyó nuevos poderes de monopolio para las grandes compañías farmacéuticas.
-
29-Mar-2018 Public Citizen
Renegotiating NAFTA: Threats to affordable medicines
NAFTA was the first “trade” agreement that included new monopoly powers for Big Pharma companies.
-
22-Mar-2018 Quartz
America messed up the idea of free trade
US-led multilateral trade agreements have forced poorer foreign countries to honor patents in exchange for the benefits of bringing multi-national corporations—and their factory jobs—abroad.
-
12-Feb-2018 East Asia Forum
Tokyo’s drift towards intellectual property crusader
Japan’s role in RCEP negotiations appears to have been shaped by its participation in the TPP. Japan is now championing for expanded intellectual property right provisions which may block access to affordable medicines
-
6-Feb-2018 Toronto Star
NAFTA will undermine health unless Canada resists monopolies on medicines
Time and again, Canadians reaffirm their belief in the basic principle of equitable access to health care for all. But the spirit of this very Canadian principle remains in peril as NAFTA negotiations forge ahead.
-
5-Feb-2018 The Wire
Delhi’s RCEP talks on intellectual property shouldn’t forget India’s role as ‘Pharmacy of the World’
India must resist pressure from Japan and South Korea in RCEP for the elevated levels of intellectual property provisions and make sure the deal doesn’t limit the production of life-saving generic drugs in India and for many other developing countries of the world.
-
1-Feb-2018 Pharmacist
Over 100 organizations concerned with health sign open letter to Canadian, Mexican and US ministers of health and trade
AIDS, cancer, religious-based, teacher, and retiree advocacy groups were among the more than 100 organizations that recently signed a letter warning health and trade ministers of the United States, Canada, and Mexico not to undermine NAFTA’s access to affordable medicines.
-
30-Jan-2018 Parti Sosialis Malaysia
Towards a peoples charter on international trade agreements
It is now time we open up the dialogue on the kind of trade agreements that we want to see in place.
-
30-Jan-2018 Knowledge & News Network
India-Cambodia deliberates on financial support in agriculture, pharmaceuticals
India and Cambodia clinch a deal to work towards a Bilateral Investment Treaty which provides financial help to Southeast Asian nations.
-
17-Jan-2018 The Hindu BusinessLine
FTA with Peru: India may have to lower import duty on drugs
India may have to lower the import duty on pharmaceuticals for Peru in the discussions on the proposed free trade agreement (FTA) with the South American country.
-
12-Jan-2018 The Hindu BusinessLine
Israel set to make a strong push for goods FTA
The present Indian government has relaunched the talks with Israel. Israel wishes to conduct talks on regular basis to conclude the deal at the earliest. Indian patent system and pharmaceutical related issues have been the reasons why the deal couldn’t progress.
-
10-Jan-2018 Deccan Herald
RCEP: India in a Catch-22
India’s position in the RCEP is the most protectionist among all the member nations. India has been resisting demands from Korea & Japan on intellectual property clauses, and other nations on opening up markets.
-
9-Jan-2018 PharmaBiz.com
As India set to sign FTA with Peru, govt seeks industry views on export import duty rates
If the trade equation between India and Peru is in imbalance it would be causing more harm than benefit to India.
-
20-Dec-2017 Health Action International
EU-Mercosur trade agreement: A bad deal for transparency, policy coherence and access to medicines
Negotiations are now nearing completion and there are increasing concerns among public health advocates, patient and consumer organisations, and other stakeholders, both in Europe and the Americas.
-
5-Dec-2017 IP Watch
O Tratado de Livre Comércio União Europeia - Mercosul coloca em risco o acesso a medicamentos no Brasil, revela um novo estudo de avaliação de impacto
As conclusões mostram que a adoção das medidas propostas pela EU poderia colocar em risco a sustentabilidade do acesso às políticas de saúde no Brasil, pois poderiam aumentar drasticamente as despesas públicas com medicamentos.
-
5-Dec-2017 IP Watch
El ALC UE-Mercosur pone en riesgo el acceso a medicamentos en Brasil, revela un nuevo estudio de evaluación de impacto
La adopción de las medidas propuestas por la UE podría poner en riesgo la sostenibilidad del acceso a las políticas de salud en Brasil, ya que podría aumentar drásticamente el gasto público en medicamentos.
-
4-Dec-2017 South Centre
South Centre statement on EU-MERCOSUR trade negotiations
EU-MERCOSUR trade negotiations must not impose TRIPS Plus provisions on protection and enforcement of intellectual property rights.
